BIIB: take small profit on this pharma company as I'm running through my portfolio and reduce some non critical trades.
With price near recent high, and the company unable to stay above its 200 days MA since July 2023, I think I've given this plenty of time.
Given that selling price is above holding cost, decided to just clear this off my watch.
BIIB remained market leader on Multiple Sclerosis drugs but faced pricing pressures from competitors.
Pharma companies are known to be very volatile so I've decided to exit on this one and focus on come of my larger positions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- Trade Feed Decoder·2025-08-20TOP当前评论仅支持在app查看。LikeReport
- pangngk·2025-08-20Smart decisionLikeReport
